Bone Graft
-
Spine
1,000 patients treated with OssDsign® Catalyst in the U.S.
Uppsala, May 9, 2023 – OssDsign AB (publ.) today announces that 1,000 patients have been treated in the U.S. with…
Read More » -
Biologics
Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia
Company plans to begin 30-patient trial later this year April 11, 2023 BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a…
Read More » -
Biologics
Induce Biologics Announces Launch of NMP Cancellous Strips
Launch is an extension to the company’s Natural Matrix Protein (NMP) family of products TAMPA, Fla., February 28, 2023 /…
Read More » -
Biologics
Comparing the Cellular Effects of Bone Graft Materials: Nanosurfaces vs. Bioglass
Biogennix, February 22, 2023 – OrthoSpineNews – Featured Article One of the critical functions of a bone graft material is to…
Read More » -
Biologics
Kolosis BIO Announces Strong 2022 Results
Kolosis bone grafts continue to gain widespread adoption, now available in over 370 hospitals and surgical facilities across 46 statesThe…
Read More » -
Biologics
Mechanisms of Action for Biologically Active Bone Graft Materials
Biogennix, November 8, 2022 – OrthoSpineNews – Featured Article Biologically active bone grafts are being increasingly favored by surgeons due to…
Read More » -
Biologics
Types of Synthetic Bone Graft Products: Active vs. Passive Materials
Advanced bone graft materials play an active role in the bone healing process by positively influencing cellular healing. Biogennix, October…
Read More » -
Biologics
Ventris Medical Receives 510(k) Clearance for Amplify® Standalone Bone Graft Putty and Bone Graft Extender
NEWPORT BEACH, Calif., Sept. 14, 2022 /PRNewswire/ — Ventris Medical, a privately held orthobiologics and tissue regeneration company, today announced that the…
Read More » -
Biologics
Cerapedics Completes Enrollment of Pivotal U.S. FDA IDE Study for its P-15L Bone Graft
The ASPIRE study is intended to evaluate the use of P-15L Bone Graft in transforaminal lumbar interbody fusion surgery in…
Read More » -
Spine
Orthofix Announces US Launch and First Patient Implants with New fiberFUSE Strip – An Advanced Fiber Bone-Graft Solution Containing Cancellous Bone
July 28, 2021 LEWISVILLE, Texas–(BUSINESS WIRE)–Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus,…
Read More » -
Biologics
Paragon 28® Inc., Expands its Novel Biologics Portfolio with Addition of Three Families of DBM
Introducing BEAST™ Injectable, BEAST PLUS™, and BEAST™ Osteobiologic Sponge (BOB™) for bone grafting applications in the foot and ankle. ENGLWOOD,…
Read More » -
Biologics
Biogennix’s Agilon Moldable Bone Graft Solution Achieves Sales Surge Amid Adoption by Foot and Ankle Surgeons
IRVINE, Calif. — May 19, 2021 — Irvine-based Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone graft…
Read More » -
Biologics
Cerapedics Announces FDA Breakthrough Device Designation Granted for P-15L Bone Graft for the Treatment of Degenerative Disc Disease
– P-15L Bone Graft is currently being studied in the Company’s ASPIRE IDE clinical trial – WESTMINSTER, Colo., April 29, 2021 /PRNewswire/…
Read More » -
Biologics
Surgalign Holdings Announce the Commercial Launch of ViBone® Moldable and the First Clinical Implantation
DEERFIELD, Ill., Jan. 12, 2021 (GLOBE NEWSWIRE) — Surgalign Holdings, Inc. (Nasdaq: SRGA), a global pure-play spine company focused on…
Read More » -
Biologics
SeaSpine Announces Publication of Results from a Cellular Bone Graft Study in The Journal of Bone and Joint Surgery (JBJS)
CARLSBAD, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on…
Read More »